Lifecore Biomedical (Nasdaq: LFCR) agreed on September 28, 2026 to be bought by Webster Equity Partners for $6.28 per share in cash plus a contingent value right (CVR) that could pay up to $3.39 more. With the stock at $6.43 on October 8, 2026, the market is paying about 15 cents per share for that CVR. Value investor @valuedontlie flagged the setup as cheap optionality, but the CVR's revenue and EBITDA hurdles sit well above Lifecore's own long-term targets.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Lifecore Biomedical, LFCR, Nasdaq.
- Situation type: Cash-plus-CVR buyout; merger arbitrage with an option attached.
- The call: @valuedontlie noted holders were paying "~30c for the optionality" when the stock traded near $6.60.
- Deal terms: $6.28 cash plus one non-tradable CVR worth up to $3.39, for a maximum of $9.67 per share.
- Deal value: Up to about $663.7 million; the cash price was a 49.5% premium to the September 25, 2026 close.
- Price: LFCR closed at $6.43 on October 8, 2026, about 15 cents above the cash price.
- Timing: A 30-day go-shop runs first; closing is expected at the end of Q4 2026.
Is Lifecore a good bet right now?
At $6.43, a buyer gets $6.28 in cash at closing and pays about 15 cents for a ticket on the CVR.
The trade-off is simple. The cash is likely if the deal closes. The CVR only pays if Lifecore grows much faster than it has said it expects to.
Why are investors interested in Lifecore?
- Small premium for a lot of upside. The CVR could pay up to $3.39, more than 20 times its implied cost.
- A big holder is on board. Wynnefield Capital, which beneficially owns 14.3% of Lifecore, signed a voting and support agreement on September 27, 2026, according to its amended 13D.
- Go-shop. A higher bid could emerge during the 30-day window.
- Committed financing. The buyer has debt commitments from MidCap Financial, MSD Partners and Alcon Research, per the 8-K.
Who's making this call and why?
@Valuedontlie is a value investor with about 12,500 followers on X who often writes about spinoffs, "stubs" and special situations.
In a September 30, 2026 post, the account summarized the deal and the math. "Stock trading around $6.60 so paying ~30c for the optionality today," it wrote. We classify this as a neutral call: it frames the price, not a direction.
Since then, the stock has drifted to $6.43, so the implied price of the CVR has roughly halved.
Track record. In our tracking of @valuedontlie's public calls, the account is 11-8 (a .579 win rate) on 19 calls scored at 180 days against the S&P 500. Its average edge of +35.1 percentage points is lifted heavily by one very large winner.
Other signals: Wynnefield's 14.3% stake and support agreement, flagged on X by @specsitsdigest, suggest at least one large holder is content with the terms.
Who disagrees, and what's the bear case?
The strongest counterargument is the CVR math itself.
- 2028 Payment ($30 million, about $0.67 per share): Requires revenue excluding Alcon of $120 million, plus either Alcon revenue of $54 million or total revenue of $174 million, per the merger announcement.
- 2029 Payment ($45 million, about $0.94): Requires ex-Alcon revenue of $175 million plus Alcon revenue of $53 million or total revenue of $228 million.
- 2030 Payment ($85 million, about $1.78): Requires consolidated EBITDA of $120 million.
Compare that with Lifecore's own guidance. It expects 2026 revenue of $120 million to $125 million and Adjusted EBITDA of $20.5 million to $25 million, per its Q2 results.
Its long-term target is 12% annual revenue growth and an Adjusted EBITDA margin above 25% by the end of 2029. By our arithmetic, 12% growth from the 2026 midpoint reaches about $154 million in 2028, below the $174 million total-revenue test.
A 25% margin on the 2029 revenue test would still be far below $120 million of EBITDA.
Wall Street is lukewarm too. Barrington Research kept a Market Perform rating after the deal, according to a post by @MarcJacksonLA.
Other risks:
- The CVR cannot be sold, so holders wait years.
- A private owner controls the business decisions that determine whether milestones are hit.
- If the deal fails, LFCR could trade back toward its pre-deal price, about a third lower than $6.28.
What are the key verifiable facts?
- Webster Equity Partners agreed to acquire Lifecore on September 28, 2026 at $6.28 per share in cash plus a CVR, valuing the company at up to $663.7 million.
- The cash price was a 49.5% premium to the September 25, 2026 closing price.
- The CVR's maximum payout totals $160 million, or $3.39 per share, across 2028, 2029 and 2030.
- Wynnefield beneficially owns 5,512,211 shares, or 14.3%.
What would prove it right or wrong?
Signals the optionality pays off:
- A topping bid appears during the go-shop.
- Lifecore's revenue growth accelerates well above 12% a year after closing.
- Alcon volumes rise sharply, helping the 2028 and 2029 revenue tests.
Signals it does not:
- The deal closes and growth tracks company targets, leaving the CVR at zero.
- Regulatory or financing problems delay or break the deal.
This is journalism and commentary, not investment advice. We hold no position unless stated.